Your browser doesn't support javascript.
loading
Neuroprotective and Anti-Inflammatory Effects of Pioglitazone on Parkinson's Disease: A Comprehensive Narrative Review of Clinical and Experimental Findings.
Zamanian, Mohammad Yassin; Terefe, Ermias Mergia; Taheri, Niloofar; Kujawska, Malgorzata; Tork, Yekta Jahedi; Abdelbasset, Walid Kamal; Shoukat, Shehla; Opulencia, Maria Jade Catalan; Heidari, Mahsa; Alesaeidi, Samira.
Afiliación
  • Zamanian MY; Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan 6718773654, Iran.
  • Terefe EM; Department of Pharmacology and Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan 6718773654, Iran.
  • Taheri N; School of Pharmacy and Health Science, United States International University, Nairobi, Kenya.
  • Kujawska M; Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
  • Tork YJ; Department of Toxicology, Poznan University of Medical Sciences, Dojazd 30, Poznan, 60-631, Poland.
  • Abdelbasset WK; Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Shoukat S; Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al Kharj, Saudi Arabia.
  • Opulencia MJC; Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt.
  • Heidari M; National Institute for Genomics and Advanced Biotechnology (NIGAB), National Agricultural Research Center (NARC), Islamabad, Pakistan.
  • Alesaeidi S; College of Business Administration, Ajman University, Ajman, United Arab Emirates.
CNS Neurol Disord Drug Targets ; 22(10): 1453-1461, 2023.
Article en En | MEDLINE | ID: mdl-36200161

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Antiinflamatorios no Esteroideos / Fármacos Neuroprotectores / Pioglitazona Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: CNS Neurol Disord Drug Targets Asunto de la revista: NEUROLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Antiinflamatorios no Esteroideos / Fármacos Neuroprotectores / Pioglitazona Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: CNS Neurol Disord Drug Targets Asunto de la revista: NEUROLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Irán